CMMB
Chemomab Therapeutics Ltd.2.0600
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
12.68MP/E (TTM)
-Basic EPS (TTM)
-1.44Dividend Yield
0%Recent Filings
8-K
CFO compensation approved
Chemomab Therapeutics appointed Sigal Fattal as CFO on June 1, 2023, with the board approving her compensation on June 14. She'll earn a $260,000 base salary, a 45% bonus potential tied to objectives, and options for 102,860 ADS at $1.70, vesting over four years with change-in-control protections. This bolsters financial leadership amid biotech challenges. Options accelerate on CIC.
8-K
Chemomab leadership shakeup
Chemomab Therapeutics shook up its leadership on June 1, 2023, reappointing co-founder Dr. Adi Mor as CEO to replace Dr. Dale Pfost and elevating VP Finance Sigal Fattal to CFO in place of Donald Marvin, while naming Dr. Nissim Darvish as board chairman. This founding team pivot aims to streamline operations amid a strategic review, suspending the Phase 2 systemic sclerosis trial to conserve cash and extend runway to end-2024 post-PSC topline data. Leadership transitions bring continuity. Yet risks linger in clinical timelines.
10-Q
Q1 FY2023 results
Chemomab Therapeutics posted a Q1 net loss of $8.8M, up 71% y/y from $5.1M, driven by research and development expenses that surged 151% to $6.9M on ramped-up clinical and preclinical work for CM-101 in fibrotic diseases. General and administrative costs dipped 16% to $2.2M, thanks to lower share-based compensation. Operating loss widened to $9.0M, while financing income rose 47% to $0.3M from interest on deposits. Cash burn hit $7.2M in operations, offset by $14.4M from deposit maturities, leaving $20.8M in cash equivalents and $11.9M in short-term deposits at quarter-end, funding operations through June 2024. No debt weighs on the balance sheet. FDA cleared the IND for a Phase 2 SSc trial in February, set to start mid-2023. Yet clinical trial delays could stretch the runway thin.
8-K
Q1 loss widens; trials advance
Chemomab Therapeutics reported Q1 2023 financials, showing a net loss of $8.8 million on $6.9 million R&D expenses, up from $5.1 million last year, while cash dropped to $32.8 million from $39.9 million. Yet the company extended its runway through mid-2024. CM-101's Phase 2 NASH trial hit safety endpoints with biomarker improvements. FDA cleared SSc IND; PSC trial advances to higher doses. Data readouts loom in H2 2024.
10-K
FY2022 results
Chemomab Therapeutics reported FY2022 net loss of $27.6 million, up from $12.5 million in FY2021, driven by ramped-up R&D spending on CM-101's Phase 2 trials in PSC and NASH, where Q4 topline data showed strong safety and biomarker improvements in liver fibrosis versus placebo. While annual expenses surged 131% y/y to $28.5 million amid clinical momentum, Q4 highlighted acceleration with positive COVID-19 lung study results validating anti-fibrotic effects. Cash burn intensified but ended at $40 million, funding operations through Q1 2024; no dividends or buybacks beyond a minor Q4 repurchase. Outlook targets SSc Phase 2 start mid-2023 and PSC topline H2 2024, yet clinical trial delays from regulatory hurdles could stall quarterly progress.
ABVX
Abivax SA
110.98-6.93
CARM
Carisma Therapeutics, Inc.
0.05+0.00
CNTB
Connect Biopharma Holdings Limi
2.36+0.06
CPMV
Mosaic ImmunoEngineering Inc.
0.40+0.00
FBLG
FibroBiologics, Inc.
0.24-0.02
IMAB
I-MAB
4.63-0.01
IMUC
EOM Pharmaceutical Holdings Inc
0.18+0.00
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
XBIT
XBiotech Inc.
2.45-0.08
YMAB
Y-mAbs Therapeutics, Inc.
8.61+0.00